Ohr Pharmaceuticals (OHRP) Downgraded by Roth Capital to “Neutral”
Ohr Pharmaceuticals (NASDAQ:OHRP) was downgraded by equities research analysts at Roth Capital from a “buy” rating to a “neutral” rating in a report released on Friday.
A number of other equities research analysts also recently issued reports on OHRP. Zacks Investment Research downgraded shares of Ohr Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 11th. ValuEngine upgraded shares of Ohr Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, December 1st.
Shares of Ohr Pharmaceuticals (OHRP) opened at $0.41 on Friday. Ohr Pharmaceuticals has a twelve month low of $0.56 and a twelve month high of $2.18. The stock has a market cap of $113.52, a P/E ratio of -0.70 and a beta of 0.48.
TRADEMARK VIOLATION NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/05/ohr-pharmaceuticals-ohrp-downgraded-by-roth-capital-to-neutral.html.
Ohr Pharmaceuticals Company Profile
OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
Receive News & Ratings for Ohr Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.